CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
Vous n'êtes pas connecté
The U.S. Food and Drug Administration (FDA) has approved Vorasidenib for patients with Grade 2 gliomas harboring Isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...
Researchers at the National Institute of Biology are exploring new avenues for more effective treatment of glioblastoma, the most aggressive form of...
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Breakthrough in triple-negative breast cancer diagnosis: New test improves early detection, offering better outcomes and personalized treatment...
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
A breakthrough in brain cancer detection offers faster, more accurate diagnoses, paving the way for earlier treatment and improved patient outcomes.